Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 149-155 , July 2010

Radiogenomics Predicting Tumor Responses to Radiotherapy in Lung Cancer

  • Amit K. Das, PhD

      Affiliations

    • The University of Texas Southwestern Medical Center, The Hamon Center for Therapeutic Oncology Research, Dallas, TX
    • Corresponding Author InformationAddress reprint requests to Amit K. Das, PhD, The University of Texas Southwestern Medical Center, The Hamon Center for Therapeutic Oncology Research, 6000 Harry Hines Blvd., Dallas, TX 75390-8593
    • ,
  • Marcus H. Bell

      Affiliations

    • The University of Texas Southwestern Medical Center, The Hamon Center for Therapeutic Oncology Research, Dallas, TX
    • ,
  • Chaitanya S. Nirodi, PhD

      Affiliations

    • Department of Radiation Oncology, Division of Molecular Radiation Biology, The University of Texas Southwestern Medical center, Dallas, TX
    • ,
  • Michael D. Story, PhD

      Affiliations

    • Department of Radiation Oncology, Division of Molecular Radiation Biology, The University of Texas Southwestern Medical center, Dallas, TX
    • ,
  • John D. Minna, MD

      Affiliations

    • The University of Texas Southwestern Medical Center, The Hamon Center for Therapeutic Oncology Research, Dallas, TX

References 

  1. Jemal A, Siegel R, Ward E. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  3. Shedden K, Taylor JM, Enkemann SA. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 2008;14:822–827
  4. Sun S, Schiller JH, Spinola M. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007;117:2740–2750
  5. Carmichael J, Degraff WG, Gamson J. Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol. 1989;25:527–534
  6. Sato M, Shames DS, Gazdar AF. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2:327–343
  7. Sabbatini P, Korenchuk S, Rowand JL. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009;8:2811–2820
  8. McDermott U, Iafrate AJ, Gray NS. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68:3389–3395
  9. Pao W, Kris MG, Iafrate AJ. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res. 2009;15:5317–5322
  10. Minna JD, Girard L. Xie Y: Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol. 2007;25:4329–4336
  11. Hwang IG, Ahn MJ, Park BB. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer. 2008;113:1379–1386
  12. Fujii T, Toyooka S, Ichimura K. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008;59:377–384
  13. Lee HW, Han JH, Kim JH. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer. 2008;59:95–104
  14. Das AK, Sato M, Story MD. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res. 2006;66:9601–9608
  15. Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):27–38
  16. Das AK, Chen BP, Story MD. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 2007;67:5267–5274
  17. Chinnaiyan P, Huang S, Vallabhaneni G. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328–3335
  18. Shibuya K, Komaki R, Shintani T. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:1534–1543
  19. Reck M, Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer. 2009;63:1–9
  20. Brognard J, Clark AS, Ni Y. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986–3997
  21. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22
  22. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: Targeted therapy. Semin Oncol. 2005;32:315–328
  23. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 2008;41:615–625
  24. Singhal S, Miller D, Ramalingam S. Gene expression profiling of non-small cell lung cancer. Lung Cancer. 2008;60:313–324
  25. Fichtner I, Rolff J, Soong R. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14:6456–6468
  26. Torres-Roca JF, Eschrich S, Zhao H. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 2005;65:7169–7176
  27. Amundson SA, Do KT, Vinikoor LC. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute anticancer drug screen. Cancer Res. 2008;68:415–424
  28. Ross DT, Scherf U, Eisen MB. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227–235
  29. Shankavaram UT, Reinhold WC, Nishizuka S. Transcript and protein expression profiles of the NCI-60 cancer cell panel: An integromic microarray study. Mol Cancer Ther. 2007;6:820–832
  30. Eschrich S, Zhang H, Zhao H. Systems biology modeling of the radiation sensitivity network: A biomarker discovery platform. Int J Radiat Oncol Biol Phys. 2009;75:497–505
  31. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004;4:309–314
  32. Bayman NA, Sheikh H, Kularatne B. Radiotherapy for small-cell lung cancer-where are we heading?. Lung Cancer. 2009;63:307–314
  33. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res. 1983;43:2806–2811
  34. Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: Current problems and future prospects. Semin Radiat Oncol. 2009;19:96–105

 Supported by NIH/NCI the University of Texas SPORE in Lung Cancer 5P50 CA 70907 (Dr John D. Minna) and NASA/DOE NASA Specialized Center of Research (NSCOR) NNJ05HD36G/DEAI0205ER64068 (Dr John D. Minna).

PII: S1053-4296(10)00010-X

doi: 10.1016/j.semradonc.2010.01.002

Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 149-155 , July 2010

Article Tools

* Image Usage & Resolution